CA2040555C - Cloned glutamic acid decarboxylase - Google Patents

Cloned glutamic acid decarboxylase Download PDF

Info

Publication number
CA2040555C
CA2040555C CA002040555A CA2040555A CA2040555C CA 2040555 C CA2040555 C CA 2040555C CA 002040555 A CA002040555 A CA 002040555A CA 2040555 A CA2040555 A CA 2040555A CA 2040555 C CA2040555 C CA 2040555C
Authority
CA
Canada
Prior art keywords
gad65
cdna sequence
gads
sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002040555A
Other languages
English (en)
French (fr)
Other versions
CA2040555A1 (en
Inventor
Allan J. Tobin
Mark G. Erlander
Daniel L. Kaufman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24346149&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2040555(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CA2040555A1 publication Critical patent/CA2040555A1/en
Application granted granted Critical
Publication of CA2040555C publication Critical patent/CA2040555C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
CA002040555A 1990-09-21 1991-04-16 Cloned glutamic acid decarboxylase Expired - Lifetime CA2040555C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US586,536 1990-09-21
US07/586,536 US6682906B1 (en) 1990-09-21 1990-09-21 Cloned glutamic acid decarboxylase

Publications (2)

Publication Number Publication Date
CA2040555A1 CA2040555A1 (en) 1992-03-22
CA2040555C true CA2040555C (en) 2003-11-04

Family

ID=24346149

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002040555A Expired - Lifetime CA2040555C (en) 1990-09-21 1991-04-16 Cloned glutamic acid decarboxylase

Country Status (11)

Country Link
US (3) US6682906B1 (de)
EP (1) EP0502188B1 (de)
JP (3) JPH05503220A (de)
KR (1) KR100220277B1 (de)
AT (1) ATE181962T1 (de)
CA (1) CA2040555C (de)
DE (1) DE69131419T2 (de)
DK (1) DK0502188T3 (de)
ES (1) ES2134199T3 (de)
GR (1) GR3031082T3 (de)
WO (1) WO1992005446A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0547164B1 (de) * 1990-09-07 2004-06-09 The Regents Of The University Of California Verfahren zur diagnose und behandlung von diabetes
US6682906B1 (en) 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
WO1992014485A1 (en) * 1991-02-22 1992-09-03 Amrad Corporation Limited A method for the diagnosis and treatment of glutamic acid decarboxylase autoantigen associated diseases
WO1992019972A1 (en) * 1991-05-03 1992-11-12 Novo Nordisk A/S Islet cell autoantigen (gad) for the detection of preclinical diabetes
JPH06508030A (ja) * 1991-05-15 1994-09-14 ザイモジェネティクス，インコーポレイティド ヒトすい島グルタミン酸デカルボキシラーゼ自己抗原のクローニング及び発現
DE4237244A1 (de) * 1992-11-04 1994-05-05 Elias Entwicklungslabor Fuer I Verfahren zur Herstellung hochreiner humaner GAD-1- und GAD-2- Proteine
WO1994012529A1 (en) * 1992-12-03 1994-06-09 The Regents Of The University Of California Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome
ZA94845B (en) * 1993-02-09 1994-11-11 Univ Monash Methods for the diagnosis of diabetes and prediabetic conditions
GB9319429D0 (en) 1993-09-21 1993-11-03 London Health Ass Methods and products for controlling immune responses in mammals
CN1112933A (zh) 1994-01-20 1995-12-06 伯伦格·曼海姆有限公司 抗原特异性活化t淋巴细胞，其检测和用途
FR2726575B1 (fr) * 1994-11-09 1996-12-20 Rhone Poulenc Rorer Sa Virus recombinants, preparation et utilisation en therapie genique
FR2717823B1 (fr) * 1994-03-23 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
IL113052A0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
SE9401118L (sv) * 1994-03-31 1995-10-01 Synectics Medical Ab GAD, en metod för framställning av modifierat GAD samt en metod för att tillföra modifierat GAD samt peptid
DE4418223A1 (de) 1994-05-25 1995-11-30 Boehringer Mannheim Gmbh Verfahren zum Nachweis des Vorliegens eines Insulin-abhängigen Diabetes mellitus
US5561049A (en) * 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
EP0815136B1 (de) 1995-02-20 2007-06-13 The Walter And Eliza Hall Institute Of Medical Research Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren
SE9503379D0 (sv) * 1995-09-29 1995-09-29 Synectics Medical Ab A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
WO1997017451A2 (en) * 1995-11-09 1997-05-15 Zymogenetics, Inc. Production of gad65 in methylotrophic yeast
US6093396A (en) * 1996-09-27 2000-07-25 Diamyd Therapeutics Ab Modified glutamic acid decarboxylase (GAD)
EP1522591A3 (de) * 1997-02-25 2005-08-17 GTC Biotherapeutics, Inc. Transgen produzierte nicht-sekretierte Proteine
US6528699B1 (en) 1997-02-25 2003-03-04 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes
AU3958999A (en) * 1999-06-01 2000-12-18 Kyokuto Pharmaceutical Industrial Co., Ltd. Method for assaying anti-gad antibody and kit
WO2001089583A2 (en) * 2000-05-23 2001-11-29 Neurologix, Inc. Glutamic acid decarboxylase (gad)_delivery system for treating neurodegenerative diseases
US7695959B2 (en) * 2000-05-23 2010-04-13 Neurologix, Inc. Glutamic acid decarboxylase (GAD) based delivery systems
US20050004001A1 (en) * 2002-10-02 2005-01-06 Robert Harris Formulation of antigen
JPWO2006098485A1 (ja) * 2005-03-15 2008-08-28 学校法人東京理科大学 グルタミン酸脱炭酸酵素変異体
TWI568847B (zh) 2007-03-16 2017-02-01 奇諾麥提卡公司 用於１，４-丁二醇及其前驅物之生物合成的組合物及方法
JP2010525049A (ja) * 2007-04-24 2010-07-22 ダイアミド セラピューティクス アーベー 自己免疫疾患及び癌を治療する薬剤及び方法
US7947483B2 (en) 2007-08-10 2011-05-24 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
CA2735883C (en) * 2008-09-10 2020-05-05 Genomatica, Inc. Microorganisms for the production of 1,4-butanediol
US8129169B2 (en) 2009-06-04 2012-03-06 Genomatica, Inc. Microorganisms for the production of 1,4-butanediol and related methods
KR20180042467A (ko) * 2009-06-04 2018-04-25 게노마티카 인코포레이티드 발효액 성분들의 분리 방법
WO2011047101A1 (en) * 2009-10-13 2011-04-21 Genomatica, Inc. Microorganisms for the production of 1,4-butanediol, 4-hydroxybutanal, 4-hydroxybutyryl-coa, putrescine and related compounds, and methods related thereto
WO2011066076A1 (en) 2009-11-25 2011-06-03 Genomatica, Inc. Microorganisms and methods for the coproduction of 1,4-butanediol and gamma-butyrolactone
US8048661B2 (en) * 2010-02-23 2011-11-01 Genomatica, Inc. Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes
US8445244B2 (en) * 2010-02-23 2013-05-21 Genomatica, Inc. Methods for increasing product yields
SI2855687T1 (sl) 2012-06-04 2020-09-30 Genomatica, Inc. Mikroorganizmi in metode za proizvodnjo 4-hidroksibutirat, 1,4-butandiola in sorodne spojine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487830A (en) 1982-05-14 1984-12-11 American Hoechst Corporation Enzyme/immunofluorescent assay for autoantibodies
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
WO1990007117A1 (en) 1988-12-13 1990-06-28 University Of Florida Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) * 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
NO306996B1 (no) 1989-02-17 2000-01-24 Bayer Ag Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk
ATE144326T1 (de) * 1990-08-17 1996-11-15 Univ Florida Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
EP0547164B1 (de) * 1990-09-07 2004-06-09 The Regents Of The University Of California Verfahren zur diagnose und behandlung von diabetes
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5998366A (en) * 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
US5475086A (en) * 1990-09-21 1995-12-12 The Regents Of The University Of California Cloned glutamic acid decarboxylase peptides
US6682906B1 (en) 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
WO1992014485A1 (en) * 1991-02-22 1992-09-03 Amrad Corporation Limited A method for the diagnosis and treatment of glutamic acid decarboxylase autoantigen associated diseases
JPH06508030A (ja) * 1991-05-15 1994-09-14 ザイモジェネティクス，インコーポレイティド ヒトすい島グルタミン酸デカルボキシラーゼ自己抗原のクローニング及び発現

Also Published As

Publication number Publication date
DK0502188T3 (da) 2000-01-24
JPH05503220A (ja) 1993-06-03
AU8877191A (en) 1992-04-15
ATE181962T1 (de) 1999-07-15
ES2134199T3 (es) 1999-10-01
US7329511B2 (en) 2008-02-12
KR920702233A (ko) 1992-09-03
EP0502188A4 (en) 1994-05-18
JP2000333671A (ja) 2000-12-05
GR3031082T3 (en) 1999-12-31
US6277586B1 (en) 2001-08-21
KR100220277B1 (ko) 1999-09-15
AU657501B2 (en) 1995-03-16
WO1992005446A1 (en) 1992-04-02
DE69131419D1 (de) 1999-08-12
US6682906B1 (en) 2004-01-27
EP0502188A1 (de) 1992-09-09
EP0502188B1 (de) 1999-07-07
JP2007236390A (ja) 2007-09-20
US20050164342A1 (en) 2005-07-28
DE69131419T2 (de) 2000-03-30
CA2040555A1 (en) 1992-03-22

Similar Documents

Publication Publication Date Title
EP0502188B1 (de) Klonierte glutaminsäuredekarboxylase
US5475086A (en) Cloned glutamic acid decarboxylase peptides
US6011139A (en) Hybridomas and monoclonal antibodies that specifically bind to glutamic acid decarboxylase peptides
US5998366A (en) Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
Tisch et al. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice
US7718386B1 (en) Methods for the diagnosis of diabetes
EP0543945B1 (de) Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes
EP0519469B1 (de) Klonierte Glutaminsäure-Decarboxylase
US6300089B1 (en) Methods and compositions for early detection and treatment of insulin dependent diabetes mellitus
AU657501C (en) Cloned glutamic acid decarboxylase used in the detection of IDDM
AU727683B2 (en) Cloned glutamic acid decarboxylase
EP0686262B1 (de) Verfahren zur diagnose von diabetes und praediabetischer bedingungen

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry